At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Apr 21, 2026 at 10:27 ET
Zentalis Pharmaceuticals announced that data from Part 1 of its MUIR trial, evaluating azenosertib in combination with paclitaxel for platinum-resistant ovarian cancer, will be presented at the 2026 ASCO Annual Meeting. While the abstract acceptance signals growing clinical interest, no efficacy or safety data are being released yet, and the event is informational rather than data-driven.
- Abstract on azenosertib + paclitaxel in platinum-resistant ovarian cancer accepted for poster presentation at ASCO 2026.
- Presentation scheduled for June 1, 2026, during the Gynecologic Cancer poster session.
- Data to be presented are from Part 1 of the Phase 1b MUIR trial, focusing on safety and preliminary activity.
- Azenosertib remains in late-stage development as monotherapy for Cyclin E1-positive PROC, with pivotal DENALI and ASPENOVA trials ongoing.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access